Vanda Pharmaceuticals
VNDA
109 hedge funds and large institutions have $571M invested in Vanda Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 34 reducing their positions, and 9 closing their positions.
331% more call options, than puts
Call options by funds: $56.9M | Put options by funds: $13.2M
267% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 9
45% more capital invested
Capital invested by funds: $393M → $571M (+$178M)
27% more funds holding
Funds holding: 86 → 109 (+23)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$19.8M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$16M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.65M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$8.96M |
| 3 |
VM
VHCP Management
New York
|
-$8.92M |
| 4 |
O
OrbiMed
New York
|
-$7.5M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$4.91M |
VNDA Hedge Fund Activity: Q1 2014 in Review
109 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2014, worth a combined $571M — up 45% from $393M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VNDA positions and 9 closed out — a net gain of 24 holders — while 32 added to existing stakes and 34 trimmed.
The largest buyer was Paulson & Co, opening a new position worth an estimated $19.8M. The largest seller was Millennium Management, cutting an estimated $9.65M.
- 109 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2014, up from 86 in Q4 2013.
- Funds reported $571M of Vanda Pharmaceuticals stock for Q1 2014, up 45% quarter-over-quarter.
- 33 funds opened new Vanda Pharmaceuticals positions in Q1 2014 and 9 closed out, a net change of +24 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2014 was Paulson & Co, an estimated $19.8M added.
- The largest Vanda Pharmaceuticals seller in Q1 2014 was Millennium Management, an estimated $9.65M sold.
Based on aggregated 13F filings for Q1 2014.